Landmark Clinical Trial Redefines Multidrug-Resistant Tuberculosis Treatment Options

Clinical trial results presented for the first time today at the Union World Conference on Lung Health revealed evidence to support the use of four new, improved regimens to treat multi-drug resistant tuberculosis or rifampicin-resistant tuberculosis (MDR/RR-TB). The team—led by Médecins Sans Frontières (MSF), Partners In Health (PIH), and Interactive Research and Development (IRD) and funded by Unitaid—formed the endTB consortium and began this Phase III randomized controlled trial in 2017. 

PIH Gives Tuberculosis Patient Broad Support for Recovery

Before becoming ill, Kaizer Mahapa, 44, worked as a street vendor in Maseru, Lesotho, selling jewelry, snacks, and fruits at two roadside stalls; one uptown in Maseru and another in his own yard.

Mahapa, who grew up in rural Lesotho, was diagnosed with HIV in 2019. Two years later, he contracted tuberculosis.  He’d never attended school, instead cared for the family’s animals. Mahapa was living with his daughter when he fell ill.

Open Letter: Requesting Clarification on the Recent Deal on Generic Bedaquiline Supply

Partners In Health Press Release 1 August 2023 Mr. Joaquin DuatoChief Executive OfficerJohnson & JohnsonOne Johnson & Johnson PlazaNew Brunswick, NJ 08933USA cc: Ms. Anna Carvaggio, Managing Director & Vice President, Johnson & Johnson;Dr. Brenda Waning, Chief, Global Drug Facility, Stop TB Partnership Open letter: Requesting clarification on the recent Read more…